Intrinsically Disordered Proteins with Professor Priyanka Joshi, Ph.D.
51 minAudio
Unlike “globular” proteins that adopt stable structures that are relatively easy to analyze, intrinsically disordered proteins adopt many context-dependent shapes. These shapes may drive diverse functions, but they are also difficult to capture and study. This represents a large gap in our understanding of biology, given that most proteins may have intrinsically disordered regions. Thankfully, researchers like Professor Priyanka Joshi, Ph.D., from Georgetown University have devoted themselves to studying intrinsically disordered proteins and are developing new approaches and leveraging new technologies like the Nautilus Voyager™ Platform to discover how their dynamic structures influence biological function. Because intrinsically disordered proteins often aggregate in disease, this work is not only essential to our understanding of biology but may also enable the development of effective biomarkers and treatments for diseases like Alzheimer’s. Parag interviews Professor Joshi on this episode of Translating Proteomics to discover: What intrinsically disordered proteins are How intrinsically disordered proteins influence biology and why they’re hard to study How the recently announced SEEDS Consortium is studying intrinsically disordered proteins Chapters: 00:00 - Introduction to Prof. Priyanka Joshi, Ph.D. 04:35 - What are intrinsically disordered proteins (IDPs)? 11:41 - When do intrinsically disordered proteins go bad in disease? 23:02 - Archetypal Intrinsically disordered proteins - c-Myc/Max, p53, and Tau 38:26 - Barriers to solving the problems associated with intrinsically disordered proteins 43:30 - The future of intrinsically disordered protein research and introducing the SEEDS Consortium Additional resources featured in the episode: https://pubmed.ncbi.nlm.nih.gov/26923286/ Joshi, Priyanka et al. “A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.” ACS combinatorial science vol. 18,3 (2016): 144-53. doi:10.1021/acscombsci.5b00129 Priyanka’s 2016 work developing small-molecule libraries to target IDPs https://www.georgetown.edu/news/georgetown-and-buck-institute-awarded-up-to-51-7m-to-predict-protein-changes-linked-to-alzheimers-and-some-cancers/ Georgetown University press release covering the SEEDS Consortium https://investors.nautilus.bio/news-releases/news-release-details/nautilus-measure-proteoforms-driving-alzheimers-disease-and Nautilus Biotechnology press release covering its involvement in the SEEDS Consortium
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Welcome back to Translating Proteomics. Today I'm very pleased to be chatting with Professor Priyanka Joshi from Georgetown University. Priyanka completed her PhD in chemistry with Professor Michaela Vendriscalo at Cambridge and was awarded a junior Research fellowship to build her independent research program in Professor Sir Chris Dobson's lab at Cambridge. She then later completed research with Paolo Piccotti at ETH Zurich and an additional bit of training with Dr. Dennis Titov at UC Berkeley. And her lab
at Georgetown investigates biophysical mechanisms by which metabolites contribute to protein homeostasis. A lot of her work focuses on what are known as intrinsically disordered proteins. These proteins have incredibly dynamic structures that enable them to take on a variety of roles in cells. And this dynamism makes. Makes them have an incredibly wide range of capabilities, but also makes them prone to an incredibly wide range of bad behavior,
particularly in diseases like Alzheimer's, where they can aggregate. These proteins are also often very hard to monitor or to develop therapeutics against because we just don't have great tools for examining their dynamic structures. But Priyanka has been developing new amazing technologies and approaches to study them ever since her time as a graduate student. So we're incredibly fortunate to have Priyanka on today to discuss her research and intrinsically disordered proteins. And so, Priyanka, welcome.
Thanks so much for being on the show. Thank you so much, Parag. I'm really excited and it's so much fun to talk about IDPs, because I've been talking about them for more than a decade now. But also the interest. Yeah, thank you so much for having me. Oh, yeah, absolutely. Well, so let's, let's start there and maybe go back in time. So you mentioned you've been studying them for a long time. What was your first experience with IDPs and why did you choose to study IDPS in the first place?
Okay, so I did not choose to study IDPs. I feel like the other way around. Like, you know, if I can joke around and say, like, they chose me. So I did my undergrad in bioinformatics in the University of Pune in India, and I was introduced to this subject called bioinformatics, which essentially had to learn about these matrices, the single letter amino acid code. And I must say that it's kind of a full circle because the matrices that were constructed by Margaret Dayhoff, she was at Georgetown. So now I'm here and
I'm studying using that single letter amino acid code in AI approaches to Understand how these proteins fold. So that was my first introduction to proteins, I would say. But then for my PhD at Cambridge, I was a research fellow as part of this consortium which was funded by the Marie Curie actions by the European Union, called IDP by nmr. So intrinsically disordered proteins by nuclear magnetic resonance. And this was a large consortium comprising
of all the stalwarts, all the experts of idp. So from day one I was kind of born into these people who were talking IDPs and were experts. And the problem that I was given was that you have to design drugs for idp. So I knew I wanted to design drugs. But then in my textbooks, you know, back from India, like I had read that proteins take this globular structure, like enzymes and they, you know, you need that. It's like sequence to structure to function. But then in this consortium that paradigm was broken,
which was, I mean the thought was like, no, in the textbooks you have the sequence. They can have many different structures depending on their binding partners and they are like promiscuous in nature and depending on what they interact with, that is what leads to function. So this was like amazingly captivating and I was like, this is, it was a very exciting and challenging problem. And also I love physics. So it was like I was, I could use, you know, NMR and computational methods to study. So that was like my first, first introduction to it.
Yeah, I mean so you were, you were, from day one, you were recognizing that the paradigm of how biology works, this sequence structure funct is sort of a gross oversimplification. And so maybe just for folks who aren't familiar, tell us just a little bit, what are intrinsically disordered proteins or intrinsically disordered regions? What do they do in the cell? Yeah, so intrinsically disordered regions are basically, they are disordered across their backbone. So they would not
occur. Like they do not have a fixed three dimensional structure. So at any given time they would occupy many, many like they would be transient. So you could have like random coil, you'll have alpha, the alpha helix. And they will, they will keep changing. So they will populate an ensemble of structures and this, this transient nature happens like super, super fast that it's incredibly hard to capture what is the structure that is, that is going to be taken. And what's interesting about these proteins is that they assume their function by their interacting by
their partner. So they might have a different structure before, but when they come in contact with the binding partner and that's when they are assuming the function and Also what's been seen is that they have residues that are quite peculiar. There could be some residues that are more disordered oriented. And that's how a lot of databases have been constructed, like, you know, for sequence based properties that can predict disorder in a protein. And something I tell my students all the time is like, if you've been given a protein sequence because everyone wants to
use alpha fold right now, please give that sequence, like put that sequence in alpha fold. And the kind of proteins we study, they come back with like 5% confidence or something. And, and that's when the story starts, which is like, you know, a lot of, I mean, the protein data bank has structured proteins. So all the missing electron densities were disordered regions. And you know,. So I think when people think about proteins, they, and they think about protein structures, they're like, okay, well there are loop regions and like the loop regions are floppy. But that's not
what you're talking about. You're not talking about an arbitrary floppy loop region. You're talking about an entire region of the protein that might have a hundred different shapes that it assumes, some of which look and are, you know, briefly structured or transition through structured regions. But it's, it's really that diversity. It's not just like, oh, I don't assume any shape, it's that I have specific families of shapes that I might adopt in a context dependent manner. Exactly. That is right. And you can think of it like a cloth
which wants to like wrap itself around, you know, a shape. And I mean a cloth can also occupy like energy, like minima. So it's almost like the most stabilized state is the one that it occupies. So like the protein would occupy. So that's the kind of, that's what IDPs are. But globular proteins would be more like, I mean, we talk about the origami. You know, they have like fixed, like a fixed shape or a fixed structure. So, so that could be like a very general comparison, I would say. And how many, I mean, is this like there are three disordered proteins
in the world? How prevalent are disordered proteins or disordered regions? I would say like research, like many researchers have shown that at least more than like about 80%, there would be at least one disordered region. And one has to think about disorder in terms of the length, the threshold. Like, what is the threshold? Because there could be a protein that could have ordered regions and disordered regions. And how do you really define disorder? Like there are proteins that have completely disordered regions, some of Them
have certain domains that are disordered and some of them that are ordered and. Yeah,. And so I think that's, that is a startling statistic for people because the viewpoint that we have is that most proteins are structured and maybe they have little bits of floppy regions. But if 80% of proteins potentially have some disordered regions within them, then this is the majority of the proteome. And, and I mean, is it, is it grand to say that some very large percent of protein
function on a proteome scale is actually driven by disordered regions or disordered proteins? Of course, yes. I, I, I get very excited by this idea because, I mean, I think of the cell as a finite volume and think of, like, when people talk about proteins, they just talk about abundances. Okay, Proteins have increased, decrease, like what happens. But if a protein is disordered, imagine, like, it can take so many different shapes and interact with so many different of its surroundings. So in that crowded environment of the cell, I feel, I mean, this
disorder is giving the protein the kind of the agency to do different things in that finite space. And that to me, like, it just kind of, it's so exciting because also it's so true because it's physics that it just makes sense. Yeah. So, I mean, this really is, I mean, as you're describing this, what's running around in my head is that the disordered regions are how proteins have functions. Whereas again, our canonical
view back in the day was that, you know, proteins like trypsin, they have function because they orient these specific amino acids in the specific shape that allows an enzymatic function to occur. And it's always that way. And maybe you talk a little bit about the lock and key mechanism, the Jacob Mono sort of model, but really thinking about proteins as these dynamic entities as opposed to these static entities. So it's not like they are, you know, they are these rigid Legos that have, you know, move a
little bit. They are really wobbly, floppy things that, and that wobbly floppiness is how they do their job. Exactly. Yeah, that is it. And it also makes sense because, like, I talk about the crowded environment of the cell, but also in terms of space, energy utilization, like biology is incredibly efficient. So if something was given, could take different shapes and different times, they could come together and catalyze a reaction and then just go back to a different shape and do something else.
So one protein having many different jobs as a function. And we had Kathryn Lilly on the show, and she was talking about how proteins can do different things in different parts of the cell. And do you think that maybe part of the way they're able to do that is that they actually have different shapes when they're in different places in the cell? Yes. And I mean, people have studied one aspect like allostery for a long time. I mean, there are still aspects of it that we need to understand. But it tells you like how something, if it's bound
to one side, it can change the shape on the other side. And so there is like, there is, it happens like proteins can change like this, this kind of interaction. So a large, like a protein can have this globally as well to, you know, to do different functions. Wow. So it sounds like intrinsically disordered regions, intrinsically disordered proteins are just critical to how cells work. Tell me a little bit about the other side. About. We, you know, we talk about tau, alpha, synuclein, some of these
other proteins as being intrinsically disordered proteins or prote proteins with intrinsically disordered regions. When do intrinsically disordered proteins go bad and become drivers of disease? So that's a very interesting question and something we want to solve. We don't know when they go bad or how. We know how to some extent, but we don't know what drives them. So to give context, proteins that are implicated in Alzheimer's hallmarks and Parkinson's,
most neurodegenerative diseases, they are disordered, more like fully disordered. And they aggregate. And these are the hallmarks. And people who have Alzheimer's in the brains. And when they aggregate, they form these giant plaques that in themselves, mechanically can get in the way of cellular processing. Exactly. So you can think of, again, look at the concept of disorder. If it is taking different shapes to interact with the partners, it can also take different shapes to misinteract or just have
the wrong interaction and be sucked into that and just get caught. And how I like to think of it is like a black hole. Like if you have some, some like a little seed, it'll just keep, you know, keep like thermodynamically, it's just going to. It's just going to grow into this larger plaque. And that's what's seen in a lot of CO pathologies as well, where you have alpha, synucle and tau altogether like their CO pathologies and we still don't know the answers, like how they land there. Is it because the cells, proteostatic machinery, it got disrupted, which does happen
with age, but maybe some cells are more resilient. So there are lots of factors that can contribute to this what we do not know is that what leads to this disordered state, to this aggregate state, what's the path? If a single, like if this monomeric protein can occupy thousands of ensembles, thousands of thousands of structures in an ensemble, which of these subset would lead to the aggregated state versus which of the subset will keep it
soluble and keep people healthy? And so you mentioned there's this gap in understanding. Why is there a gap in understanding? You hear people talk about intrinsically disordered proteins being hard to study. Why are, and you hear about them being hard to drug. Why are they hard to study? Why are they hard to drug? It's because they're hard to capture experimentally. You can take a snapshot, but if a protein is changing its shape very, very
fast, nanosecond, how do you capture that? How do you capture that scale? We need very sophisticated techniques to capture that scale. And not only like a couple of times, but across. And then which of those are relevant for disease? Which of those are druggable? Because it could be that of those many states, a few of them are forming a pocket that a drug can bind to. But that's also happening at a very small timescale. So I think it's about techniques that can help us study those proteins at the
same time having that in a time resolved manner so that we can capture all of these snapshots, you know, to, to make a movie out of it, to understand what's really happening, like the dynamic structure of these, dynamic dynamism of these proteins. So I think maybe part of what is forming in my head as you're describing this is that for right now, what we have in terms of technologies, we're really good at taking single time point pictures and we're
okay at taking movies so long as the frame rate of that movie is pretty slow. But then if we wanted to collect movies on the nanosecond timescale, we like the tools that we have available to us to look at things on that timescale are really limited. Yes, I mean, we've been using a lot of computation, like simulation.
Then the question always is that which of these structures are experimentally relevant. What some researchers have done, and Michele, my PhD advisor also did, was like using experimental restraints to restrain these simulations to tell these are the ground truths. And then you kind of of bias those, not biased, but you kind of restrain the simulations to see what is happening. So those are ways in which you can study those, like some of the ways in which you can study these dynamic structures.
Well, and that's and you know, you mentioned physics, that kind of approach of well, I can't measure the phenomenon itself, but I can measure products of the phenomenon or snapshots of the phenomenon is very common. For instance, we think about these large collider experiments where, you know, you can't actually observe the particle, but you can observe the decay products of the particle. And then that then feeds in and helps train the model to say, okay, well how, where could that have come from? It must have come from something that looked like this as opposed to something that
looked like that. Exactly, yes. So we need more data and we need to know to some like, what does that data look like? And then really use experiments and computation to kind of predict to form like, okay, these are the experiments, these are some of the snapshots we've taken. This is what it looks like in the final stage. This is what it looks like initially and maybe between healthy disease, between different kinds of diseases, the same protein causes like tau. And then put all of this information together, grounded by rules of physics and chemistry, and then see what happens.
And this demand experiments, computation and also computation at a speed that is like you cannot run an experiment on for many, many, many days or months or something. So. Yes, and so tell me today, what are the tools? You know, your lab also does, has a tremendous amount of experience with mass spectrometry. And what, what's the toolbox that people are working with experimentally today to, to study intrinsically disordered proteins? So some of the. So I can start with how people studied globular
proteins. Like people did a lot of X ray diffraction, people did X ray diffraction. And if you look at pdb, there's a lot of crystallography data which is great, which gives you electron densities. And then when people missed out those electron densities, they were like they couldn't solve the structure. So all of those regions are missing. That means that those regions are dynamic. And there are techniques like nuclear magnetic resonance that can capture that. There is small angle X ray scattering, which again is diffraction, but in solution at a small angle, which for a floppy protein,
at those small angles, you can get the radius of gy, like the shape, the radius of gyration. And you can tell what this protein would look like. You can also look at, you can also use cryo em to again to capture many, many snapshots of it. Because once the protein is kind of frozen, like in different conformations, you can use those images to build on what this structure could look like. What the range might exist because you've literally locked it in place and so you're slowing it down. It's kind of like again,
what I'm thinking about is people taking pictures with their camera and someone is running around in the background. You get this sort of blurry, smeary thing in your image. And so if you're not taking pictures at the right frame rate, you just get these blurry things, but at least you know it's in motion. Yes, exactly. And then with the cryo em you can literally stop it in its tracks and look at a wide variety of different shapes. That's true. Yeah. You can also use mass spectrometry and that's
one of the techniques that I learned in Paula Picoti's lab at ET at Zurich, which was limited proteolysis, mass spec based proteomics, which is essentially looking at the exposed regions of you know, these different regions of these proteins, these disordered proteins. So that is also one of the other techniques that one can use. Yeah. So this is a technique that people are probably not familiar with. So maybe just say a little bit more about how people
are used to shotgun mass spectrometry where you know, you digest everything and you denature the proteins first. But in the method you're describing, this is done in a very different way. Where can you maybe just tell us a little bit about how, how limited proteolysis actually helps you learn about protein structure? Yes. So there are certain non specific proteases like that are, that exist which can, which can have non specific cleavage sites. And one of them like, you know, if you use like proteinase K, it's going to cleave at non specific sites. So if a protein is
folded in say like one structure, it's, it'll only have access to certain sites. But if it's folded in a different structure it's going to have access to different sites. And if something is bound down to it like a drug or a ligand, it's going to have again the accessible sites differ. So this like proteinase K can have like, it's limited proteolysis because it's going and activate like looking at non specific sites and then what you get are basically conformitypic peptides which essentially represent like a fingerprint of what, what the, what, what, what
the different structures could like, what they could look like. So you can basically say that if there is a protein that exists in a couple of different structures in a dis, you can perform this method and see what could These different states look like in different patients and get like a fingerprint, a structural fingerprint. Yeah. So I mean, the way that I think about it is you essentially have this messy ball of yarn, which is your protein structure, and then you've got a set of scissors. And the scissors can only get to the little strands that are on the surface of that messy
ball of yarn. And so if you see a cut in a row in a particular region that says, oh, okay, this must have been on the outside of the ball of yarn as opposed to buried in the middle of the ball of yarn. And the mass spec is really helping you see where the sites of the cuts were, where the scissors were able to act, and that you may see a range of sets of different answers come back. And the ratios and prevalences can shift when you drop a drug in
or you change the ph or even when you introduce another protein potentially. Yes, absolutely. That's a really good example, really good way of looking at it. For our readers who want to learn about this space. Can you maybe give me an example of the archetypal IDP that has multiple different structures that act in different ways, drives different biological functions and sort of what your favorite example paper
is from talking about that protein? Yeah, so I think I would have different proteins depending on the context, what we study as well. So I would start with the paper that inspired me to study IDPs was this interaction between C. Myc and Max. They're oncogenic proteins and they are completely disordered on their own, but they come together and assume an structure and that, that. So, and there, there can be small molecules that can, that can disrupt this and that's. And, and, and it's
been super hard to even study those interactions. So that's, that's one of the, that's one of those two, two proteins that, that, that, you know, I would, that though that's one. The second is P53MDM2 interaction. And it's very interesting because, you know, I meet some people who say like P53 has been studied for a long, long time. We know everything. I've even met people who are like, oh, this person, you know, like is the P53 person. But they did not study disorder. They did they like, you know, they, they
did not study that. P53 has these, it's not completely disordered, but it has both ordered and disordered domains and depending on that it engages with its targets and causes. Like, has different functions and it is, it's almost like sitting in a hub and Then you have like these network of protein interactions and I, and still we haven't been able to understand all of those interactions. So if someone really, really is excited about like, because there's so much information about this, this, this protein set that, that, that I would, I would encourage them to read. And the other
protein which is my favorite protein is tau for, for reason that I study it. But I think it's a, it's an, a challenging, enigmatic, fun protein to work with because it also causes like disease, but there are also functional aspects of it. Understand. So this is like the more challenging aspect that people may not be able to find more, but that's where we are sitting right now to understand it better. That's very interesting. And with P53 people often talk about how it has two very different functions. One is DNA damage sensing
and the other is DNA damage response. And is it believed that maybe that split in its behavior and function is actually related to its IDP properties? Maybe. Yes. Yeah. Wow, that would be amazing. Priyanka, I wanted to ask you about one of your papers from 2016, this really beautiful work on fragment based method for creating small molecule libraries for developing therapeutics for intrinsically disordered proteins.
Maybe first tell us just a little bit about that work and then what I'm curious about is you published that paper maybe a decade ago now. If you were to redo that study or extend that study today, how would it look different? Yeah, so that's the paper that really got me excited and that's the work that I did during my PhD at Cambridge. And so what we've showed is that because there are no druggable pockets like normal globular proteins and IDPs and they have pretty much extended structures,
how can we design small molecule drugs to bind to those and change the course of aggregation? So in this paper, basically what I show is that you can take different fragments of known binders and then combine them in novel ways to make better binders that can slow down the aggregation of these IDPs, which in particular in my case what I've shown it is an amyloid beta. And I think there is something in that which is which, which we
still need to understand, which is like what are the rules? What are the rules of these small molecule, you know, these, these drugs. Because if you can break them into fragments and then recombine them and make something better, then maybe there is a rule to make it, to combine it and make it better. And that's why I say like chemistry based AI Maybe we can find those rules now. And it's not just the rules in these drug molecules, but also on the IDP side because this is, is an IDP which is completely disordered and having, giving all these large surface areas, maybe there are rules in the arrangement of these amino
acids, in the way the exposed, you know, the solvent axis is there. So together I think like now using physics and chemistry based AI, so like more advanced, like getting more measurements, we can, we can, we can answer this question better to get these drugs. But what's even more fascinating is, and what, what basically inspired my research from that paper and that study was that after that work I saw like in my library of small molecules, there were molecules that looked like ATP, gluc, small metabolites.
And I asked the question that if synthetic chemists can design drugs, then nature over the course of evolution must have designed small molecules that keep proteins stable inside the cell. And that's when I wanted to work into environment and metabolites to know that, okay, how does, how does this really work? And that just makes so much sense to me. It's just that we need more data and more mechanistic, you know, to, to actually understand that. So, so that's, that's where my journey began. And I feel we can do so much more based off that.
You know, it's interesting you saying this. I had a conversation with my graduate advisor, David Eisenberg about, about intrinsically disordered proteins and aggregation and, and what he was saying. I, I honestly thought he was kind of nuts when he was describing this because he was saying, oh well, you know, I think part of what is driving this aggregation is actually not protein protein interactions, but potentially protein nucleotide interactions. I was like, that is not something that I ever thought about as exogenous factors,
either RNA or even, you know, nucleosides, nucleotides interacting with proteins and then causing them to behave in a completely different way. But that sounds, based on what you're saying about adp, et cetera, right in line with. Absolutely. And I can go an hour talking about those interactions because there have been super like studies by others that have shown that ATP, they can form these, you know, they can face separate and then they can cause and trigger. But we can go, we can talk
a lot about that. Well, no, that's great. Yeah. And so what is your hope? So it sounds like that's the set of tools, that's the tools that we have today. And if we are wildly successful in understanding intrinsically disordered proteins, what does that do for us? How does that help us? I mean, a large number of diseases are caused, like the proteins that are implicated are intrinsically disordered. So we're talking about disease. When we're talking about impact, we're
talking about disease here. So, I mean, I'm interested in neurodegenerative diseases. And in that, like, what a wild success for me would look like is that if I could look at these proteins and then really follow their path and understand that why do they fold or misfold in one person under certain conditions and not in the other? So for that, capture the path of those proteins, look at it from the different states of it and really distinguish
between healthy versus disease states, because that's going to be essential. And that's actually important for drugs to work as well, because a large number of drugs that are failing and, you know, like, that are not successful in every patient population is because people's proteins, like these shapes and aggregates, they might be different. And it might be that the drugs we are making are just made for one kind of, you know, the yarn, the ball, the yarn that you're making. But there could be that maybe some yarn is like, maybe has a little, like, I don't know, like a little.
Has a divot in it, for instance. Yeah, exactly. Something so, so, so, so that could be. And I think if we could capture those, like what these range of, I mean, you know, different proteoforms, like, if I can use that word now, like, you know, if what they could look like, then we can really distinguish that what are the healthy ones versus disease ones. And then we can make effective drugs that would actually work for most people rather than just a certain set of people. No, that makes a lot of sense. And that's a good segue to talk about
proteforms. So we've talked about how proteins have a wide range of shapes and structures. We've also in the past mentioned proteoforms and how they can be decorated and have phosphorylations and methylations and truncations, et cetera. Talk to me a little bit about your personal beliefs in the connection between proteoforms and intrinsically disordered protein ensembles. And what do you believe the connection is there between
the two? Yeah, so I'll take my favorite example, which is tau, which I'm also working on, which is like, there's this one protein that misfolds and causes a range of tauopathies. It aggregates in different parts of the brain, causing different diseases and all progress at a different rate. In some people very fast and some people very slow. It causes different kinds of dementia. It's the same protein. And what I think is that it just meets different environments. Of course there could be some genetics, maybe not in tau, but in
the surrounding environment of the cell. And which, which deems like either resilience to the cell or you know, disruption. But, but, but so that's how I define the path and I. And when the cell's environment is not favorable, that is contributing to this protein getting, occupying these different ensembles that are maybe more sticky, that kind of interact more with the surrounding regions and that just causes the cell to die or more
disruption. And maybe there are other confirmations that are not so much that are, you know, like that. I mean, think of it like a person walking down a room and kind of getting and talking to different kinds of people and kind of, you know, maybe sticking to a crowd, but other crowd. So I think that's how these disordered proteins are also behaving inside the cell. And depending on what they are interacting with and where they are sitting and aggregating and growing into these structures can help us tell us tell what is disease and not. And I think we need both kinds of approaches,
which is both fundamental where we are engineering these hypothesis driven and at the same time from the patients where we are collecting a lot of data samples and then looking what these proteins look like and then kind seeing that, okay, can we ask this question and can we kind of see what the outcomes would be? So I think that is. Sort of going both forwards and backwards of saying, all right, if we poke at the protein in this way, or we construct a triple phosphorylated form, what does it look like? And then going from
the patient side and saying, all right, what are the set of flavors of proteins, of variants of proteins that exist and what is their phenotypic behavior and consequence and trying to meet in the middle between that ground up very mechanistic view and that more clinical translational perspective. Exactly. You said the right word, which is mechanistic view. And that's what we need. We need the mechanism and the data to kind of converge. That makes a lot of sense. So carrying on our theme of just understanding
a little bit more about proteoforms, maybe a little bit of a cause and effect question for you. Do you believe that a proteoform identity, so its set of PTMs and truncations, et cetera, drives IDP structure? Or do you believe that the IDP structure drives the formation of different proteoforms. That's a very, very interesting question. And I would think of it both ways. So. So you know, when a protein is synthesized
like after translation, it's also like co folding and it's. There are lots of things that are happening to it. So if you think of it that way, then whatever is happening to the protein could drive its different proteoforms. So it's like it's occupying many, many ensemble, like many, many different states. But then the one that is most stabilized is the one that is the proteoform in that given. In that given. So it's basically trying that energy minima. And it's basic. It's the moment it finds it,
it becomes that proteoform. And that proteoform could tell us whether it's disease or not. Maybe. So that's one way of thinking about it. The other is you might have proteoforms that can trigger other idps to misfold or fold differently. Like you could have like a seed which, a nucleation, which can seed like nucleation and maybe change the other proteoforms to, you know, change
their shape and then settle into something else. So I think I just want to summarize a little bit. It sounds like what you're saying is it goes both directions that and it goes as a network effect. So that a particular protein inhabiting one of a series of proteoforms or a set of proteoforms could drive differential IDP behavior in its friends and neighbors. And then likewise, depending upon its set of interactions that could lead to different forms of a protein being made in the first place.
You know, opening up a site for phosphorylation or opening up a site for cleavage. Yes, absolutely. Yeah. That's incredibly complicated, but makes a lot of sense that biology doesn't isolate one action. It uses the tools at its disposal in a lot of different ways. And really what you're articulating is that there's this very tightly coupled relationship between proteoforms and IDP ensemble structures.
Yes. Because, yeah, they're just finding. I feel like there are many, many, if I had to visualize it, it's like there are so many structures just going together and then there are. Is they. They find the energy minima and then they, they, they form that one protoform and that triggering thing could be maybe a ptm, could be a condition or could be a mutation as well. Could be, could be anything. That is just making them go into that proteoform. Like. That's, I'm going to be percolating on that for a while.
And so you know, just from your perspective, what, so we, we talked a little bit about gaps in measurement. What are the other, are big barriers today to solving these problems of intrinsically disordered proteins? What are you most excited about in your lab that we're tackling this really big problem that's going to help us in this way? Yes. So in my lab I'm looking at what are the environments that could again let these proteins fold or misfold. And I think that
is one problem. Like we don't even know how to recreate these in like what are the model systems to use? How do we even start? Like, where do we even start? Like a lot of proteins that I've been using are expressed in E. Coli, which do not have post translational modifications. And then I'm doing these very sophisticated biophysical measurements on that, which is very exciting too because I get to know some very basic rules. But then when I connect them to actual human patient biology, it's not translating. And what I see is
like a lot of the translation gap. Like there are zero percent drugs that have been successful that came out of mice, for example. So it's like what my lab is trying to do, what I'm trying to do is bridge this fundamental knowledge like biophysics and then really bring it to what it means for patients, like the medical impacts. And what this could look like is looking at maybe doing some, some key biophysical experiments in the context of aging. So you know, looking at maybe patient like acquired, like
material and then trying to come up with sophisticated methods or advanced methods to understand like can I, can I, can I bridge these two? So I think that is my goal, which is very fundamental, very basic questions and then applying that to patient outcomes. That's very interesting. I think one of the things that when sort of looking at some of your most recent papers, you were very much looking at protein variants. So in addition to context and environment, but questions of how isoforms potentially affect
the set of shapes that can exist. And looking across not just in Alzheimer's disease, but this also seems to just be prevalent in cancer as, as well. And so in your mind when you, when we learn these things, it opens up, it opens up new diagnostics, it opens up potentially new types of therapeutics that are different than what we're applying today. What, what else does this really
enable? Once we're able to study both the structural side and the proteoform side and put them together. So I mean, if you were to think of it from a disease diagnostic therapeutic point of view,. Then. We can really have better companion diagnostics as well because we, if we can understand how a protein is changing its shape and if we are able to detect it early on, then we can, we can really design a drug that binds to that shape shape and doesn't let
it progress towards an aggregated state. So we can really have both diagnostics and therapeutics looking at these proteins rather than just drugging the protein and being like, yeah, we're going to find a drug, but here we can track it in people and then giving it to drugs. However, what I'm also fascinated about is it's not just disease. There are also functional amyloids and these are intrinsically disordered proteins and they can also form functional stuff. So are also these proteins, they can
give rise to materials. And there are like, I mean when I was a PhD student I would see like a lot of slides showing spider silk which is like that's also protein. So you know, so, so these disordered proteins can be made to also like because they make functional materials. We can also use them in synthetic biology to like there's like a whole new toolkit that, that can be opened if you just understand the grammar or you know, the rules of these IDP is like how they fold, misfold and like what they're
doing. That's, that's really crazy because I think, you know again when we think about biomaterials, we tend to think of wanting things that are incredibly structured and have a very specific shape that comes from what they do. But I think what you're saying is there's actually an entire other set of, of if you had idps you could create even newer, more interesting materials for further that are that go beyond what we've been able to create so far. Yeah, I mean it's. It. Yeah, definitely because they can do so
many different things. It's just that only if we knew how to and to. If like, you know, to do that we need to understand those rules. How, how are they, how are they misfolding? Folding, not misfolding, but folding into all these different shapes. That's neat. Well, so tell. Maybe I'd like to transition a little bit to the, to just talking about the future and, and we just announced Congratulations. This large ARPA H funded consortium focused on intrinsically disordered proteins that you're co leading called seeds. Tell me a little bit about seeds. What it's
hoping to do sort of its long term goals. Yeah. So also congratulations to you because Nautilus is our partner in this consortium. I am so excited to get to work on this with you. It's going to be a lot of fun. Yeah, it's going to be, it's like it's a dream project and this is exactly what I've been wanting to study for the last like many, many years. And it was just the perfect opportunity to bring all the fun people doing exciting things who can make this project possible for the question we've asked together. So
in this SEEDS project we're answering that question. We're looking at how the environment and how the context is changing the shapes of these intrinsically disordered proteins. And we have partnered with Buck Institute for Research on Aging to form a super team. We have 10 academic partners and seven industry partners including Nautilus, whose the Voyager platform we'd be using to understand these isoforms, these proteoforms. And the goal for this project is to really understand IDPs across like in breadth
and in depth. So I always liken this to you know, reading, understanding the grammar of like other style of an author which is like either read many books or just read one thing deeply enough to understand different ways of like what is the, what are the semantics. And that's exactly what we are doing. So we're going to look at many, many proteins and then we'll focus on two proteins which are tau and EWS fly one which is implicated in Ewing sarcoma, which is a pediatric cancer and tau is implic Alzheimer's disease,
but also a range of taupathies. So we're really looking at how these proteins in different contexts, in different environments change their shapes. And then we will look at which of these shapes are related to a healthy outcome versus a diseased outcome. And we are bringing in different techniques altogether. So we are using high throughput and high resolution techniques. We have a cell free protein expression platform
that can make thousands of variants at a time and we can expose it to thousands of conditions. You can think of what different permutations we can expose it to. And then we have a physics and chemistry based AI model that helps us use a lot of of this experimental biophysical data as restraints to capture what is possible. So AI can't do this on its own. The language models because there are force fields,
there are rules. So we are really bringing in physics, chemistry, a breadth of biology, also patient biology. So we have clinicians on our team as well and we have patient cohorts who we'll be validating all our results into. So we not only like having like a hypothesis driven, data driven and we are predicting and then we are validating it into a disease. So this makes the whole consortium like, like a big giant. Like it's a dream project, that's what I call it because we are like we have everyone delivering
onto solving one part of the puzzle. And this whole puzzle is like how does the environment change the shape of these proteins and leading to health or disease? Disease. And I think one of the challenges, the reason that all of the protein structure tools you mentioned, alphafold, they're dependent upon having a significant data corpus and people have been chipping away at the globular protein corpus since myoglobin and lysozyme. Way back the very first sperm whale myoglobin
structures were solved. But for IDPs we just don't have the data resource to build the next generation models. And because they're so complex we really do need these physics informed models that, so we have a gap both in the training data and in the just AI methodologies to incorporate physics based models alongside the other canon. Exactly. Yes. That's very exciting. So going far? Future. Future. So 10 years
from now, looking back, what, what do we now know about IDPs and how have they influenced the world? This is just a total prediction. There's no right answer. But from, from your viewpoint, you're looking back on the last 10 years of your career and on the field, where are we? I think we will have a foundational model that can predict these different ensembles of structures and tell what they are
and from a health impact outcome. Knowing this knowledge will help us. We will be at a point where we have a diagnostic test that can predict which of these proteoforms are associated with different diseases. Diseases. So it's not just getting a multi omic, you know, a biomarker, like a panel, but it's really about these structures of these proteins and like people knowing which disease they have. Because currently it's super hard to diagnose Parkinson's, like people going with psp, cbd, they don't, they get a wrong
diagnosis. So, so, so 10 years from now what I see is like people getting diagnosed early, which is helping families, but also drugs that are actually successful and available to people that, that, that can really, that can really address the, the cause of the disease. Yeah, that's, that's where I, that, that's where I would hope. But the other side of me also hopes to see like the functional aspects of these IDPs with, you know, people coming up with cool functions to, you know, like using them because
they are proteins, they're the workhorses of the cell, they can do a lot of different things. So maybe using them in more creative and foundational ways of, of creating new things. That's a very exciting vision. Thank you again for joining us today. Just to sum up for our listeners, I think our key take homes are that drive basically all of biology, but that they've been pretty hard to study so far and that's why they're not talked about as much and why we don't understand them as well. Work that
Priyanka and her colleagues are doing is really trying to open that black box so that we can understand how these critical proteins make biology go, make disease go, and then to modulate that in the future. And so it sounds like this is a very exciting moment for IDP biology where all these things are coming together to really transform the next decade. Yes, I'm super excited and I'm super excited to be working together as well on this project Problem. Oh, it's going to be so much fun. So thank, thank you everyone
for joining us today on Translating Proteomics. Thank you to my guest Priyanka Joshi for joining us and sharing her perspective. Super fun having a chance to chat with you. Thank you. Thank you so much, Parag. It was super fun chatting with you as well. Thanks. We hope you enjoyed the Translating Proteomics podcast brought to you by Nautilus Biotechnology. To contact us or for further information, please email translatingproteomicsautilus
Professor Brendan Keating’s lab focuses on “advancing the field of organ transplantation” and employs multiomic techniques to improve outcomes for both allo- (human to human) and xeno- (animal to human) transplantation....
Translating Proteomics hosts Parag Mallick and Andreas Huhmer discuss our new Nature Methods paper, “Large-scale single-molecule analysis of tau proteoforms.” This publication describes how the Nautilus Voyager™...
On the latest episode of the Translating Proteomics podcast, Nautilus VP of Scientific Engagement and proteomics industry expert Sheri Wilcox joins hosts Parag Mallick and Andreas Huhmer for a thought-provoking...
Professor Olga Vitek has a deep understanding of statistics, machine learning, and computational biology. She puts her know-how to work to develop computational tools enabling high-quality proteomic analysis and systems...
Host Parag Mallick chats with Professor Afshin Beheshti who is a Professor of Surgery, Director of the Center for Space Biomedicine, and Associate Director of the McGowan Institute for Regenerative Medicine at the...